Detail akcie Esperion Therap online

Business Summary: Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Esperion Therapeutics Inc revenues decreased 53% to $65M. Net loss totaled $40.5M vs. income of $61M. Revenues reflect Collaboration revenue decrease of 73% to $30.1M. Net loss reflects Interest Expense increase of 39% to $19.4M (expense), Interest Income decrease of 54% to $1.1M (income), Other income, net - Balancing value decrease from $377K (income) to $28K (expense).